share_log

普利制药(300630.SZ):马来酸曲美布汀片通过一致性评价

Pri Pharmaceuticals (300630.SZ): Trimebutine maleate tablets passed the consistency evaluation

Gelonghui Finance ·  May 14 05:55

Gelonghui, May 14 | Puli Pharmaceuticals (300630.SZ) announced that it recently received a notice from the National Drug Administration (“NMPA”) that trimebutine maleate tablets passed the consistent evaluation of generic drug quality and efficacy. Trimebutine maleate is a synthetic anticholinergic drug that inhibits contraction caused by acetylcholine through a non-competitive manner, and is mainly used to treat gastrointestinal disorders and irritable bowel syndrome.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment